ArticleInfection and drug resistance2025
Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and tolerability of linezolid to treat tuberculosis: a systematic review and meta-analysis.Respiratory research & clinical practice · 2026Pooled it
- High-dose linezolid during BPaL implementation for pre-extensively drug-resistant TB or failure/intolerance of rifampicin-resistant TB regimens.IJTLD open · 2026Article
- Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review.IJTLD open · 2026Review
- Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infectious diseases and therapy · 2026Review
- Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Safety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China.Infection and drug resistance · 2026Article
- From linezolid to contezolid: a strategy for safe continuation of therapy in complex tuberculosis.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Linezolid is a core drug used to treat rifampicin-resistant tuberculosis (RR-TB) and multidrug-resistant tuberculosis (MDR-TB). However, adverse events (AEs) have limited its clinical application. Safer alternatives to linezolid are needed to address the safety concerns. Patients and Methods: A total of 27 patients with RR-TB (including MDR-TB) were randomly assigned to receive either contezolid (n=14) or linezolid (n=13) in combination with standardized background anti-TB regimens, that is, linezolid-bedaquiline (pyrazinamide)-levofloxacin (moxifloxacin)-cycloserine-clofazimine or contezolid-bedaquiline (pyrazinamide)-levofloxacin (moxifloxacin)-cycloserine-clofazimine. The dosage was 600 mg q12h for linezolid, and 800 mg q12h for contezolid. AE data were collected during the 2-month treatment period to analyze the characteristics, severity, onset time, duration, drug relatedness, management, and outcome of the adverse drug reactions. Results: The median (range) age of contezolid- and linezolid-treated patients was 40.9 (26-65) and 36.7 (18-65) years, respectively. The incidence of AEs was 14.3% (2/14) in contezolid-treated patients and 92.3% (12/13) in linezolid group. All drug-related AEs in contezolid group were gastrointestinal reactions (nausea and vomiting one case each). No peripheral neuropathy or myelosuppression AEs were observed. The AEs in linezolid group included anemia (30.8%, 4/13), peripheral neuropathy (53.8%, 7/13), and gastrointestinal reactions (23.1%, 3/13). Dose reduction or discontinuation was required for linezolid in 84.6% (11/13) of patients. The anti-TB efficacy of contezolid and linezolid was comparable in terms of sputum culture conversion rate and imaging-confirmed lesion absorption rate after treatment for 2 months. Conclusion: Contezolid may be a safer alternative to linezolid based on AE incidence in the treatment of multidrug-resistant tuberculosis for two months. Clinical Trial Registration: This study was registered at https://www.chictr.org.cn (identifier: ChiCTR2300074234).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.